Great Basin Moving POC MDx Platform to Market; Eyes Summer Clinical Trials for First Two Tests

The company has developed a cartridge-based, multiplex, sample-to-answer molecular testing platform in the same vein as Cepheid, and hopes to begin clinical trials for its first two tests for detecting Staphylococcus aureus in blood culture and Clostridium difficile in stool by early summer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.